BMJ 2003;326:64-65 ( 11 January )

Editorials

Testing new pharmaceutical products in children

A positive step, but ethical concerns remain

The first 150 words of the full text of this article appear below.

Ideally all medicines that could benefit children should be licensed for this purpose. To date this has been the exception rather than the rule, resulting in children becoming therapeutic orphans sometimes with tragic consequences. Many medicines prescribed for children, whether in hospital or primary care, are either unlicensed or off label (used for an indication, age, dose, or route of administration outside the terms of the product licence). ^{1 2} Other problems surround the prescribing, dispensing, and administering of medicines to children.³ Many difficulties could be overcome if manufacturers were obliged to test their products on children as well as adults.

In the United States a "carrot and stick" approach has been adopted to achieve this end.⁴ The carrot is the "paediatric exclusivity provision," which grants an additional six months of patent protection or market exclusivity to companies that voluntarily test the relevant drug on children. The stick is the "paediatric rule," . . . [Full text of this article]

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    StumbleUpon    Technorati    What's this?

Relevant Articles

Drug use in children: cohort study in three European countries

Miriam C J M Sturkenboom, Katia M C Verhamme, Alfredo Nicolosi, Macey L Murray, Antje Neubert, Daan Caudri, Gino Picelli, Elif Fatma Sen, Carlo Giaquinto, Luigi Cantarutti, Paola Baiardi, Maria-Grazia Felisi, Adriana Ceci, Ian C K Wong on behalf of the TEDDY European Network of Excellence
BMJ 2008 337: a2245. [Abstract] [Full Text] [PDF]

Rational prescribing for children

Alastair G Sutcliffe and Ian Chi Kei Wong
BMJ 2006 332: 1464-1465. [Extract] [Full Text] [PDF]

Post-marketing surveillance is needed for off licence use of drugs in children

Michael Tettenborn
BMJ 2003 326: 712. [Extract] [Full Text]

This article has been cited by other articles:

• Sturkenboom, M. C J M, Verhamme, K. M C, Nicolosi, A., Murray, M. L, Neubert, A., Caudri, D., Picelli, G., Sen, E. F., Giaquinto, C., Cantarutti, L., Baiardi, P., Felisi, M.-G., Ceci, A., Wong, I. C K, on behalf of the TEDDY European Network of Excelle, (2008). Drug use in children: cohort study in three European countries. BMJ 337: a2245-a2245 [Abstract] [Full text]  
• Sutcliffe, A. G, Wong, I. C. K. (2006). Rational prescribing for children.. BMJ 332: 1464-1465 [Full text]  
• Webb, E (2004). Discrimination against children. Arch. Dis. Child. 89: 804-808 [Full text]  
• Everard, M L (2003). Ethical aspects of using radiolabelling in aerosol research. Arch. Dis. Child. 88: 659-661 [Full text]  

Rapid Responses:

Read all Rapid Responses

Barriers to accessibility of efficacious and safe medicines for children

David M Reith
bmj.com, 10 Jan 2003 [Full text]

LIPIL and newborn human test subjects

Denny Rice
bmj.com, 10 Jan 2003 [Full text]

a new ethic in the 21st century

Andre R Menache
bmj.com, 10 Jan 2003 [Full text]

Post marketing Surveillance for Paediatric Drug use off license.

Michael Tettenborn
bmj.com, 11 Jan 2003 [Full text]

Online poll

Find out more >>